Bicycle Therapeutics plc - American Depositary Shares (NQ:BCYC)

3.380 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bicycle Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Deep Dive Into Bicycle Therapeutics Stock: Analyst Perspectives (9 Ratings) ↗

February 26, 2025

Via Benzinga

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

February 25, 2025

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 05, 2025

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 03, 2025

From Bicycle Therapeutics plc

Via Business Wire

Forecasting The Future: 11 Analyst Projections For Bicycle Therapeutics ↗

January 13, 2025

Via Benzinga

Breaking Down Bicycle Therapeutics: 8 Analysts Share Their Views ↗

December 16, 2024

Via Benzinga

Navigating 11 Analyst Ratings For Bicycle Therapeutics ↗

October 24, 2024

Via Benzinga

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

January 13, 2025

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 09, 2025

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 03, 2025

From Bicycle Therapeutics plc

Via Business Wire

In-Depth Examination Of 5 Analyst Recommendations For Bicycle Therapeutics ↗

September 06, 2024

Via Benzinga

Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

December 18, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 13, 2024

Via Benzinga

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

December 13, 2024

Via Benzinga

Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients ↗

December 13, 2024

Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 gene amplification.

Via Benzinga

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

December 12, 2024

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

December 10, 2024

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 02, 2024

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

November 25, 2024

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference

November 12, 2024

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 01, 2024

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

October 31, 2024

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

October 23, 2024

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress

October 16, 2024

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 02, 2024

From Bicycle Therapeutics plc

Via Business Wire

BCYC: A Promising Play In The Biotech Sector ↗

October 01, 2024

The long-awaited and overdue half-point cut in the federal funds rate was the impetus for the SPDR Biotech ETF to finally break above the 102-103 level. Meanwhile, Bicycle Therapeutics Plc. had a...

Via Talk Markets

Topics ETFs

Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024

September 14, 2024

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone ↗

September 06, 2024

RBC Capital initiates coverage on Bicycle Therapeutics, highlighting Zelenectide's potential in oncology with improved safety over competitors. The analyst projects ~$2 billion in peak sales by 2033...

Via Benzinga

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 03, 2024

From Bicycle Therapeutics plc

Via Business Wire

Bicycle Therapeutics to Participate in Upcoming Investor Conferences

August 21, 2024

From Bicycle Therapeutics plc

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.